Conduit Pharmaceuticals Inc. received notices from Nasdaq for failing to meet minimum market value requirements for publicly held shares ($15 million) and listed securities ($50 million), giving them until February 11, 2025, to regain compliance; additionally, the company discovered undisclosed share dispositions by a director and formed committees to investigate trading patterns.